TOBREX
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPS
Approved
Dec 1980
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
TOBREX by Novartis is clinical pharmacology in vitro data: in vitro studies have demonstrated tobramycin is active against susceptible strains of the following microorganisms: staphylococci , including s. Approved for the treatment of external infections of the eye, its adnexa caused by susceptible bacteria. First approved in 1980.
Drug data last refreshed 6h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TOBREX is a tobramycin ophthalmic solution approved in 1980 for bacterial eye infections. It is a small-molecule aminoglycoside antibiotic delivered as topical drops directly to the eye. The drug works by inhibiting bacterial protein synthesis to treat gram-negative and some gram-positive ocular pathogens.
$0.057MPart D
LOE ApproachingLow commercial intensity with modest Part D volume signals a niche mature product with minimal team expansion opportunities.
Mechanism of Action
CLINICAL PHARMACOLOGY In Vitro Data: In vitro studies have demonstrated tobramycin is active against susceptible strains of the following microorganisms: Staphylococci , including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains.…
Indications (2)
Worked on TOBREX at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.